Matthew Dagley

Director of Marketing and Development at CVRx - Barostim Therapy for HFrEF: Out Smart the Heart. Chicago is 🏠 🏳️‍🌈👨🏾‍🤝‍👨🏼🇺🇸🐶🐱 (tweets are my own)

[CVRx | Barostim @CVRx_Barostim]

We were proud to support Dr. Victor D'Addio, Dr. Peem Lorvidhaya, and the team at Mary Washington Hospital on their first #Barostim implant. Their patients now have access to a novel device therapy to improve symptoms of #heartfailure.

[CVRx | Barostim @CVRx_Barostim]

Stob by and visit us at #AAHFN2026 this week to learn how #Barostim + GDMT can improve quality of life for patients with #heartfailure.

[CVRx | Barostim @CVRx_Barostim]

Today we recognize the researchers and healthcare professionals advancing the science behind better patient care. Clinical trials play a critical role in expanding treatment options, improving outcomes, and deepening understanding of disease and therapies. We’re grateful to their dedication to move healthcare innovation forward. #ClinicalTrialsDay

[CVRx | Barostim @CVRx_Barostim]

Today we announced our 1st quarter financial results and provided a business outlook for 2026. We are pleased to share these milestones:

-Increased total revenue by 20% over prior year quarter
-Increased US revenue by 22% over prior year quarter
-Active US implanting centers grew to 257, as compared to 227 as of March 31, 2025
-First site activated and first patient enrollment in BENEFIT-HF clinical trial

"We delivered a strong start to 2026, with U.S. revenue growing 22% as the investments we made in our team and programs throughout 2025 begin to translate into results," said Kevin Hykes, President and Chief Executive Officer of CVRx. "We are seeing continued progress from our sales organization and the successful activation of the first site and our first patient enrolled in our BENEFIT-HF clinical trial. Together, these developments reinforce our confidence in the path ahead and in our ability to make Barostim more accessible to heart failure patients."

Learn more: https://t.co/hZigR7WpjY

[CVRx | Barostim @CVRx_Barostim]

Congratulations to Dr. Orvar Jonsson, Dr. Mark Fleming, and the team at North Central Heart - a division of the Avera Heart Hospital - on successfully completing the first #Barostim implant in the landmark BENEFIT-HF trial! We're proud to partner with leading physicians and their teams in the development of meaningful clinical evidence.

[CVRx | Barostim @CVRx_Barostim]

Congratulations to Dr. Fazal Ali, Dr. Matthew Montgomery, Dr. Eman Rashed, Dr. Cindy Sturt, Dr. Jonathan Lee, Dr. Kunal Vani, Dr. Jonathan Levison, Angela McCall Brown, and the team at Newark Beth Israel Medical Center on their 25th #Barostim implant! Thank you for your dedication to providing innovative therapy options to improve the lives of patients with #heartfailure.

[CVRx | Barostim @CVRx_Barostim]

Visit us at #ACC26 this weekend to learn how GDMT + #Barostim - a novel device therapy that targets the neurohormonal pathway - can significantly improve exercise capacity and quality of life in patients with #heartfailure beyond GDMT alone.

[Dr. Sheila Sahni @DrSheilaSahni]

Airport warning for the #ACC26 crowd! ✈️ Leave a minimum of 2 hours to get through security. I'm well over an hour into the CLEAR + TSA Pre line. See you all in NOLA (eventually)! 🎷

[CVRx | Barostim @CVRx_Barostim]

Enhance your knowledge about #Barostim and its role in #heartfailure management through this #ACCEd virtual course. You'll learn about:
-The stages of heart failure where Barostim is useful
-Patient selection criteria
-How Barostim complements guideline-directed medical therapy
-The impact of a multidisciplinary team approach in optimizing Barostim for improved patient outcomes in heart failure management

Access the course: https://t.co/TgiQsw7dJu

[CVRx | Barostim @CVRx_Barostim]

Join us at #ISHLT2026 for “Barostim: Flipping the Parasympathetic Switch,” where expert faculty will explore how #Barostim works alongside GDMT to address the neurohormonal drivers of #heartfailure. Drs. Peter Eckman, @shelleyhallmd, Matthew Danter, and @fsheikh22 will review key evidence, patient selection, surgical considerations, and share strategies for building successful multidisciplinary programs. They’ll also explore what’s next, including insights into the emerging BENEFIT-HF trial.

Add to calendar: https://t.co/dqXBE5GDtU

[CVRx | Barostim @CVRx_Barostim]

Lisa’s #heartfailure made even simple daily tasks exhausting and impacted not only her, but her son as well. Following #Barostim therapy, she has regained energy, independence, and the ability to return to everyday activities like cooking and grocery shopping on her own.

[CVRx | Barostim @CVRx_Barostim]

We were proud to partner with Dr. Cyril Varughese, Dr. Mohammad Alqaim, and the team at Medical City Fort Worth on their first #Barostim implant. Their patients now have access to a novel device therapy to improve symptoms of #heartfailure.

[CVRx | Barostim @CVRx_Barostim]

Congratulations to Dr. Manuel Perez-Izquierdo, Dr. Hector Lozano, and the heart failure, cardiology, and vascular surgery teams at AdventHealth on reaching the milestone of 250 #Barostim implants! Thank you for your dedication to advancing innovative therapy options and improving the lives of patients living with #heartfailure.

[CVRx | Barostim @CVRx_Barostim]

We were proud to partner with Dr. Scott Reishus, Dr. Ali Valika, Dr. Owais Malick, and the team at Advocate Good Samaritan Hospital on their first #Barostim implant. Their patients now have access to a novel device therapy to improve symptoms of #heartfailure.

[CVRx | Barostim @CVRx_Barostim]

We were honored to support Dr. Georges Haidar, Dr. Ashish Haryani, Dr. Baqir Lakhani, and the team at Ascension Alexian Brothers on their first #Barostim implant. Their patients now have access to a novel device therapy to improve symptoms of #heartfailure.

[CVRx | Barostim @CVRx_Barostim]

Thank you to our outstanding faculty — Philip Adamson, MD, Melissa Wendell, FNP-BC, Michael Gajewski, AGACNP, and Jessica Griffiths, PA-C — for leading an insightful Advanced Practice Providers (APP) Summit this week in Nashville!

From highlighting the critical role of APPs in identifying, staging, and managing patients for #Barostim to sharing best practices for incorporating the therapy into a comprehensive #heartfailure program, the meeting was packed with valuable discussions and actionable takeaways. We’re grateful to the 50 APP attendees for their engagement throughout the program and dedication to advancing heart failure care.

[CVRx | Barostim @CVRx_Barostim]

The #Barostim procedure now uses Category I CPT codes as of Jan. 1, 2026. Explore the updated codes: https://t.co/A2eJY2iYU2

[CVRx | Barostim @CVRx_Barostim]

Heading to #THT2026? Don’t miss our Satellite Program, “Targeting the Neurohormonal Cascade with #Barostim.” You’ll hear the latest advances in evidence on Barostim from Philip Adamson, MD, MSc, FACC, FESC, FRCP (Ed), Gabriel T. Sayer, MD, @fsheikh22, MD, and @DmitryYaranovMD.

Mark your calendar: https://t.co/8AZEekwbMD

📅 Tuesday, March 3rd
⏰ 12:15 pm – 1:30 pm
📍 Omni Seaport, Ensemble CD South

[CVRx | Barostim @CVRx_Barostim]

Today we announced our fourth quarter and full year financial results and provided a business outlook for 2026. We are pleased to share these milestones:

-Increased total revenue by 10% over prior year
-Active US implanting centers grew to 252, as compared to 223 in the prior year
-Initiated the BENEFIT-HF trial with first enrollments expected in Q2 2026
-Category I CPT codes and the related favorable physician fee payment levels took effect Jan. 1, 2026

Learn more: https://t.co/GYeJk2TlLK

[CVRx | Barostim @CVRx_Barostim]

Thanks to @shelleyhallmd and @hfdocbhimaraj for the engaging discussion at #UCARS26 on #Barostim and how to integrate therapy options into a comprehensive #heartfailure program.